Lugano (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, today announced that it has signed a Distribution and License Agreement for Aloxi® (Palonosetron hydrochloride) and Gelclair® in Germany with Riemser Arzneimittel AG, a medium-sized pharmaceutical group engaging in research, headquartered in ...
Lugano, Switzerland (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, is pleased to announce, ahead of schedule, today's launch in the UK of Aloxi® (Palonosetron hydrochloride), a new generation treatment for chemotherapy induced nausea and vomiting, by its local partner Maelor plc, the specialist hospital medicines group. Aloxi® is a patented ...
LUGANO, Switzerland and MINNEAPOLIS, MN (ots) - Helsinn Healthcare S.A., Switzerland, a privately owned pharmaceutical group and its partner, MGI Pharma (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that a supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Capsules for oral ...
Zug (ots) - AmVac AG has a new executive officer on board - Dr. Wolfgang Schmidt agreed to join the company in early December to lead its operational business. Dr. Wolfgang Schmidt is a graduated chemist who began his career with Hoechst AG in Frankfurt/Main, Germany. After a variety of stints in pharmaceutical research, he directed the site-management Frankfurt department in the lead generation research segment. ...
Witterswil (ots) - Biolytix AG (www.biolytix.ch) signed a service provider agreement with Affymetrix UK Ltd (www.affymetrix.com) and offers genomic analysis services for the academic and industrial R&D community under conditions compliant with a stringent quality management system. Biolytix, one of the ...
Lugano (ots) - Oral Formulations of 5-HT3 receptor Antagonists Represent Approximately 10% of the Day-of-Chemotherapy Market - Helsinn Healthcare SA, a privately owned Swiss pharmaceutical group, and its partner MGI PHARMA, INC., (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, ...
TRB Chemedica International S.A.
Geneva (ots) - TRB Chemedica International S.A. has issued legal proceedings against Gilead Science Limited in a dispute over the distribution rights of their products Viread, Hepsera, Truvada and Emtriva for Switzerland. TRB Chemedica International S.A., a small, family-owned Swiss pharmaceutical company based in Geneva, was granted exclusive rights by ...
Paris (ots) - At this year's 7th congress of the European Society of Gynaecology (Paris, 10-14 October 2007), the German pharmaceutical company Grunenthal GmbH presents the latest study results for its oral contraceptive Belara®. As the first of its kind the dermatological CEFIS-Study* of the University of Hamburg shows an impressive cosmetic improvement of impured skin due to the anti-androgenic properties of ...
Former Cedi-Diagnostics new affiliate for the Benelux and Nordic markets Zurich (ots) - Prionics, a world leader in farm animal diagnostics, enhances its own presence in Europe targeting the Benelux and Nordic markets with the launch of Prionics Lelystad (Netherlands). The latest affiliate emerges from the former Cedi-Diagnostics B.V. acquired in 2006, a spin-off from today's world-famous Animal Sciences Group of ...
Aachen (ots) - At this year's 4th World Congress of the World Institute of Pain (WIP), the German pharmaceutical company Grunenthal GmbH presented the latest clinical data on its centrally active analgesic tapentadol in acute pain. Tapentadol combines two analgesic principles in one molecule, μ-receptor ...
London (ots) - Helsinn's Top Management today announced the positive outcome of the EMEA procedure, according to Article 107, initiated due to concerns over serious liver problems. The Committee for Medicinal Products for Human Use (CHMP) today confirmed Nimesulide's positive benefit/risk profile. The benefits of these medicines outweigh their risks, but there ...
Zug (ots) - As of September 1, 2007 Ariane Meynert is joining Swiss biotech company AmVac AG, Zug, as Managing Director in charge of investor and public relations. Management graduate Meynert comes from TOMORROW FOCUS AG in Munich, a Hubert Burda Medien AG Group company where she was in charge of developing investor and public relations for several years. She previously supervised, in the same function, the ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins® in ophthalmologic disease. The studies reported by Pieris relate to PRS-055, an ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins® in ophthalmologic disease. The studies reported by Pieris relate to PRS-055, an Anticalin® ...
Ingelheim, Germany (ots) - For scientific media outside the USA, Canada and Japan Boehringer Ingelheim announced today that it is undertaking a new initiative in the treatment of heart attack (ST-segment elevation myocardial infarction or STEMI). The company will sponsor a new clinical trial known as ...
Plan-les-Ouates (ots) - Viroblock SA, a start-up dedicated to developing and commercializing a new generation of antiviral products, today announced that it has completed its first round of equity funding led by private investor Peter Pfister, Fongit Seed Invest SA, and Initiative Capital Romandie SA. Viroblock also announced that the newly appointed Board of Directors will consist of Peter Pfister (Chairman), ...
Aachen (ots) - The German pharmaceutical company Grunenthal announces its worldwide exclusive rights on trimegestone for the use in oral contraception by Aventis Pharma, SA, France, a subsidiary of sanofi-aventis. Thereby the firm extends its gynaecological pipeline. Trimegestone will be developed as a new oral contraceptive component derived from natural ...
PDUFA date of 4th March 4, 2008 established Lugano (ots) - Helsinn's Top Management today announced that the supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting was accepted for filing by the United States Food and Drug Administration (FDA). Aloxi is approved by the FDA ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for the potential treatment of asthma. In studies of its proprietary ...
Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today that its proprietary Duocalin® technology has successfully demonstrated dual targeting potential. Commenting on this development, Dr ...
Aachen (ots) - The German pharmaceutical company Grunenthal GmbH presented the first clinical evidence for the efficacy and tolerability of tapentadol ER (extended release) for patients suffering from chronic pain at the Annual Congress of the European League Against Rheumatism (EULAR), 13-16 June 2007, Barcelona, Spain. Tapentadol, a centrally acting analgesic, ...
Barcelona (ots) - New Results Represent Additional Data From a Study Showing Superior Efficacy of ORENCIA or Infliximab Compared to Placebo at Six Months Bristol-Myers Squibb Company (NYSE: BMY) today announced additional study results providing evidence of the efficacy and durability of response of ORENCIA(R) (abatacept) through 12 months in adults with ...
Anti-Tumor Necrosis Factor (TNF) Therapy in Inadequately Responding Rheumatoid Arthritis Patients Barcelona (ots) - According to a new study, it is possible to safely switch directly to ORENCIA® from anti-TNF therapy in rheumatoid arthritis patients who have had an inadequate response to anti-TNF therapy. The results were announced today by Bristol-Myers ...
Lugano (ots) - With reference to the Irish Medicine Board (IMB) decision, mainly based on 6 cases of hepatic damage, to suspend the marketing and sale of nimesulide and following the request to the European Committee for Medicinal Products for Human Use (CHMP) to revise the benefit/risk profile of the drug, Helsinn Healthcare deems opportune to specify that nimesulide is a drug with a positive safety profile as ...
Lugano (ots) - HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced that a supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting (PONV) has been submitted to the U.S. Food and Drug ...
Winterthur (ots) - SpineLab AG, a privately held company, specialized in developing a dynamic stabilization system for the spine, announced today that it has raised CHF 4 million in a first financing round. Lead investors are BioMedInvest and VI Partners. Other participants are the management and Acceleration International. Gérard Moufflet, CEO and Founder of Acceleration International has been appointed Chairman of ...
Berlin (ots) - ProBioGen and Minapharm jointly announced today that they have entered into two separate agreements to develop two therapeutic proteins, one exclusively for Minapharm and another second generation biopharmaceutical product for co-promotion. In the first agreement, ProBioGen will apply its proven cell generation process for biopharmaceutical cell ...
Freising-Weihenstephan (ots) - Pieris AG, a bio-pharmaceutical company developing therapeutic products comprising of Anticalins®, a novel proprietary class of human binding proteins, announced today it has demonstrated potent anti-tumor activity of PRS-050. The positive results with PRS-050, a VEGF-specific ...
Zurich (ots) - Prionics, a world leader in farm animal diagnostics, has received approval for the extended use of its Johne's disease test Parachek®. With the original test kit for the diagnosis of paratuberculosis, the United States Department of Agriculture (USDA) has for the first time officially validated ...
Aachen, Germany (ots) - Grünenthal GmbH announced that it has extended a licensing agreement with Ortho-McNeil Pharmaceutical, Inc. for tapentadol to include the Japanese market. Ortho-McNeil Pharmaceutical plans to arrange for the development of tapentadol for marketing in Japan. Ortho-McNeil"s affiliate, ...